OPKO Health, Inc. (OPK)
| Market Cap | 2.51B |
| Revenue (ttm) | 1.91B |
| Net Income (ttm) | 70.91M |
| Shares Out | 647.00M |
| EPS (ttm) | 0.11 |
| PE Ratio | 33.55 |
| Forward PE | 74.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,809,451 |
| Open | 3.66 |
| Previous Close | 3.70 |
| Day's Range | 3.63 - 3.70 |
| 52-Week Range | 3.02 - 6.27 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 6.60 (+78.9%) |
| Est. Earnings Date | Oct 28, 2021 |
About OPK
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OPKO Health stock is "Buy." The 12-month stock price forecast is 6.60, which is an increase of 78.86% from the latest price.
News
Should you buy OPKO Health shares? Analysts remain bullish despite the pullback
On Monday, Opko Health Inc. (NASDAQ:OPK) shares edged slightly higher after Jefferies and Piper Sandler analysts issued upbeat statements following Friday's decline. The OPK stock price slipped more tha...
OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Gr...
NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review...
GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today ann...
OPKO Health (OPK) Forms JV, Establishes Presence in China
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in ...
SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversif...
Best Reddit Penny Stocks To Buy Now? 5 For Your List In September 2021
Which Reddit penny stocks are on your watchlist right now? The post Best Reddit Penny Stocks To Buy Now?
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpati...
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The U.S....
OPKO Health to Participate in Two Upcoming Investment Conferences
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New Yor...
CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), anno...
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal...
Top Penny Stocks to Buy? Why These 3 Should Be on Your Watchlist
Are these penny stocks worth watching with the stock market down today? The post Top Penny Stocks to Buy?
3 Hot Biotech Penny Stocks to Watch With High Volume in 2021
Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
Why Opko Health Shares Shriveled by Nearly 8% on Friday
The coronavirus stock didn't impress with its Q2 results.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
OPKO Health (OPK) Reports Q2 Loss, Misses Revenue Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
MIAMI, July 20, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, ...
7 Reddit Penny Stocks About to Explode
With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on Inv...
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.
OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology
OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.
OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy
OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizi...
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) f...